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Abstract
Background: Nephropathia epidemica (NE) is a mild form of hemorrhagic fever with renal syndrome (HFRS) that is
caused by the Puumala virus. Periodic outbreaks have been described in endemic areas, with a substantial number
of previously healthy individuals developing acute kidney injury (AKI). There is a considerable diversity in the clinical
course of the disease, and few patients require renal replacement therapy.
Methods: We tested whether urinary neutrophil gelatinase associated lipocalin (uNGAL), urine albumin/creatinine
ratio (uACR), urine protein/creatinine ratio (uPCR), urine dipstick protein, C-reactive protein, procalcitonin, leukocyte
and platelet count, determined on admission to the hospital, can predict the severity of AKI. Sixty-one patients
were analyzed during admission in the emergency department.
Results: The variables most strongly associated with peak plasma creatinine concentration were uNGAL (β = 0.70,
p <0.0001), uPCR (β = 0.64, p = 0.001), uACR (β = 0.61, p = 0.002), and dipstick proteinuria (β = 0.34, p = 0.008). The
highest AUC-ROC to predict stage 3 AKI according to the acute kidney injury network’s (AKIN) classification was
seen for uNGAL (0.81, p = 0.001).
Conclusion: uNGAL accurately predicts the severity of AKI in NE. This could help emergency room physicians
predict disease severity and allow for initial risk stratification.
Keywords: Hantavirus, Nephropathia epidemica, Acute kidney injury, NGAL, Neutrophil Gelatinase-Associated
Lipocalin, Puumala virus infection, Hemorrhagic fever with renal syndrome
Background
Nephropathia epidemica (NE) is a common cause for
acute kidney injury (AKI) in otherwise healthy persons
living in endemic regions. Although it is a relatively mild
form of hemorrhagic fever with renal syndrome, the fre-
quency of periodic outbreaks has increased over the last
years, and the increasing number of infections with high
rates of hospitalization makes it an emerging public health
threat [1]. NE is caused by the Puumala virus (PUUV), a
member of the Hantavirus genus. The virus is spread
through aerosolized excrements of distinct rodents, the
bank voles (Myodes glareolus), while the rodents them-
selves are probably asymptomatic carriers [2]. In 2012
there were 2824 cases of NE reported in Germany, repre-
senting the highest incidence since the introduction of a
mandatory nationwide register in 2006 [3].
PUUV infections manifest after an incubation period
of 2–4 weeks starting with non-specific flu-like symptoms
such as fever and headache. A considerable proportion of
infections may have a subclinical course or only cause
light symptoms [4]. Acute kidney injury (AKI), often intro-
duced by severe flank pain and oliguria, is a potentially
serious consequence which can lead to fluid retention,
hyperkalemia and the need for renal replacement therapy
in some cases [5, 6]. We recently showed that the use of* Correspondence: nils.heyne@med.uni-tuebingen.de1Department of Internal Medicine, Division of Endocrinology, Diabetology,
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non-steroid anti-inflammatory drugs in the acute phase
is associated with a more severe disease [7]. Up to now,
there is no established method to predict the severity of
AKI upon onset of symptoms or admission. Therefore,
patients with clinically suspected and/or serologically
proven PUUV infections are usually hospitalized for
observation. A marker reliably predicting the severity
of AKI would be of clinical relevance, since it could aid
emergency-room physicians in triaging patients with
suspected or confirmed NE.
In this study, we tested the association of plasma and
urinary laboratory parameters with disease severity in
patients with NE who have been admitted to our neph-
rology unit through the emergency room (ER) of the
university hospital. The investigated parameters comprised
leukocyte and platelet count, plasma C-reactive protein
(CRP) and procalcitonin (PCT), plasma sodium, urinary
protein-to-creatinine ratio (uPCR), urinary albumin-
to-creatinine ratio (uACR), urine dipstick protein (semi-
quantitative measurement), urinary neutrophil gelatinase
associated lipocalin (uNGAL), the ratio of NGAL to
creatinine in urine (uNGAL/uCrea). Neutrophil gelatinase
associated lipocalin (NGAL) in urine or plasma is an emer-
ging marker of AKI, which has been shown to correlate
with severity of AKI [8]. NGAL is a small protein in mono
and multimeric forms with a size of approximately 25-kDa
[9]. It is expressed in neutrophils and human epithelia espe-
cially of liver and kidney tissue.
Because of its size, NGAL is filtered in the glomerulus
and reabsorbed in the proximal tubule. Urinary NGAL
can discriminate between acute allograft rejection and
AKI of other causes [10].
Methods
Study population
We retrospectively identified 61 patients with NE who
were admitted to our nephrology unit through the ER of
the university hospital in 2012. The Ethics Committee of
the Tübingen University Medical Faculty has waived the
need for informed patient consent for this retrospective
analysis (Reference: 049/2015R). Anonymized data on
anthropometric parameters, duration of hospital stay,
quantity of maximum urinary output and weight change,
defined as the difference between the highest and lowest
recorded weight during hospital stay, were extracted by
chart review. The assessed laboratory parameters com-
prised leukocyte count, platelet count, CRP, PCT, initial
plasma creatinine, peak plasma creatinine during hos-
pital stay, uPCR, uACR, dipstick proteinuria, uNGAL,
uNGAL/uCrea and serologic status. PUUV infections
were confirmed by IgM and IgG-capture ELISA and in
doubt proven by Western Blot. A positive reaction in
IgM-ELISA was necessary for study-inclusion.
Laboratory analysis
Laboratory measurements were performed in the central
laboratory of the university hospital as ordered by at-
tending physicians. Blood cell and platelet counts were
determined on the ADVIA 2120 hematology analyzer.
Semiquantitative proteinuria (“urine dipstick protein”) was
determined using the iChemVELOCITY urinalysis system
(Iris Diagnostics, Beckman Coulter, Krefeld, Germany).
Urinary albumin levels were measured nephelometrically
(BN Prospec Nephelometer). Urinary protein was deter-
mined using the benzethonium chloride method (Roche
Diagnostics, Mannheim Germany) and CRP was deter-
mined using a wide-range latex-enhanced immunturbidi-
metric assay. Plasma and urine creatinine was measured
enzymatically using the creatinase method and urinary
concentrations of NGAL were determined using a particle-
enhanced turbidimetric immunoassay (BioPorto Diag-
nostics, Gentofte, Denmark). Plasma sodium and all other
measurements above were performed on an ADVIA 1800
clinical chemistry analyzer (all instruments from Siemens
Healthcare Diagnostics, Eschborn Germany).
PCTconcentrations were determined using the BRAHMS
KRYPTOR Time Resolved Amplified Cryptate Emission
Immunoassay system (Thermo Scientific, Hennigsdorf,
Germany).
Calculations and statistical analysis
The severity of AKI was evaluated according to the sta-
ging system devised by the Acute Kidney Injury Network
[11]. The increase of creatinine was used as the main
marker of the severity of AKI (increase of creatinine to
equal or more than 3-fold of the baseline creatinine value).
None of the patients had previously known chronic kidney
disease. Therefore, basal creatinine values were estimated
from normal glomerular filtration rates that are nor-
mal for sex and age, standardized on body surface area
(1.73 m2) [12]. To calculate normal plasma creatinine
levels, creatinine levels were backtraced from the CKD-EPI
equation (Chronic Kidney Disease Epidemiology Collabor-
ation) by solving the equation for this variable.
Furthermore, we calculated length of hospital stay and
retrieved data on body weight and urine output from
analyzed charts. Change of body weight during hospital
stay was calculated by subtraction of the lowest measured
weight from the highest measured weight.
For statistical analysis in this study, we decided to use
uNGAL raw data including quantitative values below the
limit of quantification of 25 ng/ml, defined by a coefficient
of variation ≤20 %. In patients with no detectable uNGAL
concentration, the value of 1 ng/ml was used instead of
zero, to enable log-transformation.
Results of the semiquantitative urine protein meas-
urement approximately correlate with albuminuria as
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follows (+) 0.1 ~ 0.5 g/L, + 0.5 g/L, ++ 1 g/L ~ 3 g/L
and +++ over 3 g/L.
Univariable linear regression analyses were used to assess
the association of possible predictors with peak plasma
creatinine. In multivariable linear regression analyses,
predictors were adjusted for sex, age and BMI. Estimates
are given as standardized betas (βstd).
Parameters with skewed distributions were log-transformed
prior to analyses.
Receiver operating characteristic (ROC) curves were used
to assess the discriminative power of investigated predictor
variables of severe AKI. All statistical calculations were per-
formed with JMP 11.0 (SAS, Cary, NC, USA).
Results
We identified 61 patients with serologically confirmed NE
who were admitted to our nephrology unit during 2012.
None of the patients required hemodialysis. Patient charac-
teristics with descriptive data on investigated biomarkers
and outcome variables are shown in Table 1 (for distribu-
tion of uNGAL levels, see Additional file 1: Figure S1).
Peak plasma creatinine concentration
While platelet count, CRP and procalcitonin did not
show significant correlations with peak plasma creatinine
concentration, uNGAL and markers of proteinuria (urine
dipstick proteinuria, uACR and uPCR) were associated
with it (see Table 2 and Fig. 1). Controlling for the poten-
tial confounders sex, age and BMI did not relevantly
change these associations (see Table 3). The use of the
normalized variable uNGAL/uCrea instead of uNGAL did
not confer further improvement in the β-estimate.
To test whether the association between uNGAL and
peak plasma creatinine concentration is independent from
proteinuria, we fitted uNGAL to peak plasma creatinine
concentration in multivariable linear regression models
also controlling for uACR or uPCR. Adding covariables of
albuminuria (pACR =0.03) or proteinuria (pPCR = 0.04)
did not abolish the significant association of uNGAL
and peak plasma creatinine (pNGAL = 0.002 in both
models). Actually, the effect size estimate for uNGAL
was numerically substantially higher than for uACR
(βstd = 0.55 vs 0.35) or uPCR (βstd = 0.57 vs 0.35) in
these combined models.
When testing the association between uNGAL and peak
plasma creatinine concentration with additional adjust-
ment for sex, age, BMI and uACR, uNGAL maintained its
strong association. Even the association between uNGAL
and duration of hospital stay was not affected (see Table 4).
Acute kidney injury, AKIN stage 3
uNGAL and markers of proteinuria significantly and rele-
vantly predicted a rise of plasma creatinine consistent with
AKIN stage 3 (see Table 5, also see Additional file 1: Figure
S2). The highest AUC-ROC was shown for uNGAL. Data
in the ROC-table (see Additional file 1: Table S1) show
that taking an NGAL cutoff of >130 ng/ml achieves a high
specificity (specificity 91 %) and a high positive predictive
value (90 %) for stage 3 AKI. A cutoff of ~30 ng/ml
yielded a relatively high sensitivity for developing stage 3
AKI (sensitivity 90 %, negative predictive value = 75 %)
(see Table 6).
Other clinical variables of disease severity
Among the investigated clinical variables, uNGAL was
significantly associated with hospital stay and weight
change during hospital stay (see Table 2). Interestingly,
platelet counts at admission associated with the length of
hospital stay (see Table 2) but not with peak creatinine.
The association between platelet count and hospital stay
was stronger after controlling for sex, age and BMI (see
Table 3), suggesting a negative confounding by sex, age
and BMI. However, none of the covariates sex, age, and
BMI associated with length of hospital stay in univariate
Table 1 Demographic, clinical and laboratory parameters of the
study population (N = 61)
Median IQR
Age (years) 45 33, 52
Sex (m/f) 45/16
BMI (kg/m2, n = 58) 24.5 22.5, 28.6
Days between onset of symptoms and
hospital admission
6 4, 7
Length of inpatient stay (days) 7 5, 9
Span of body weight change during hospital
stay (kg, n = 56)a
4.2 2.3, 5.8
Highest urine output per 24 h (ml, n= 56) 5850 4500, 8300
Leukocyte count at admission (1/μl) 8680 6685, 10725
Platelet count at admission (thousand/μl) 109 71, 178
Plasma Sodium (mmol/l) 135 132, 139
C-reactive protein at admission
(mg/dl, n = 60)
6.3 3.9, 9.6
Procalcitonin at admission (ng/ml, n = 19) 1.27 0.9, 1.9
Estimated baseline creatinine (μmol/l) 86 82, 89
Plasma creatinine at admission (μmol/l) 221 106, 344
Peak plasma creatinine (μmol/l) 344 185, 618
Patients with AKIN stage 0–2/3 23/38
Urinary protein/creatinine ratio
(mg/g, n = 23)
1492 552, 10303
Urinary albumin/creatinine ratio
(mg/g, n = 24)
1007 223, 8440
Urine dipstick protein (neg/(+)/+/++/+++,
n = 59)
2/6/17/28/6
Urinary NGAL (ng/ml, n = 55) 83 31, 189
Urinary NGAL/creatinine ratio (ng/mg, n = 49) 137 43, 371
ahighest documented weight – lowest documented weight
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Table 2 Correlation of laboratory markers with variables of disease severity; a. univariate
Peak plasma creatinine Duration of hospital stay Weight cycling Peak urine output
R2 βstd (p) R
2 βstd (p) R
2 βstd (p) R
2 βstd (p)
Leukocyte count 0.08 0.28 (0.026) 0.03 0.17 (0.185) <0.01 −0.0 (0.99) 0.01 −0.09 (0.489)
Platelet count 0.00 0.02 (0.888) 0.08 −0.29 (0.024) 0.06 −0.26 (0.06) 0.03 0.17 (0.214)
Plasma sodium 0.11 −0.33 (0.010) 0.09 −0.30 (0.021) 0.09 −0.29 (0.03) 0.00 −0.02 (0.902)
C-reactive protein 0.01 −0.12 (0.381) 0.02 0.16 (0.236) <0.01 −0.05 (0.72) 0.09 −0.30 (0.029)
Procalcitonin 0.12 0.35 (0.145) 0.20 0.45 (0.055) 0.09 0.30 (0.22) 0.04 −0.19 (0.442)
Urine protein/creatinine 0.41 0.64 (0.001) 0.06 0.25 (0.256) 0.05 0.23 (0.32) 0.00 −0.03 (0.912)
Urine albumine/creatinine 0.37 0.61 (0.002) 0.15 0.38 (0.065) 0.15 0.38 (0.07) 0.00 −0.02 (0.934)
Urinary NGAL 0.50 0.70 (<0.0001) 0.31 0.56 (<0.001) 0.09 0.31 (0.03) 0.00 0.00 (0.999)
Urinary NGAL/creatinine 0.47 0.69 (<0.0001) 0.22 0.47 (0.001) 0.09 0.31 (0.03) 0.00 0.03 (0.837)
Fig. 1 a–f Correlation of possible predictor variables. Correlation of possible predictor variables with peak plasma creatinine concentration during
hospital stay. In panels (a, b, c, d and f) both axes are log-scaled. Only the y-axis is log-scaled in panel (e). Panel (e) shows category means +− SDs
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analyses. Out of the other investigated biomarkers, plasma
sodium, CRP (after adjustment only) and dipstick protein-
uria associated with length of hospital stay. There was a
negative association of CRP with peak polyuria, which
may have been confounded by sex, age and BMI.
Discussion
In this study, we provide first evidence that uNGAL, as
a point of care variable determined in emergency room
(ER) patients having symptoms compatible with PUUV,
is a good predictor of the severity of AKI due to PUUV
infection. Although markers of proteinuria (uACR, uPCR
and semiquantitative proteinuria determined by dipstick
test) also correlated with the severity of AKI, these associ-
ations were weaker and uNGAL preserved a considerably
stronger association with peak creatinine in models ad-
justed for uACR or uPCR. The highest discriminatory
power for severe AKI, defined as AKIN stage 3, among the
investigated variables was observed for uNGAL.
Our study delivers a proof-of-principle that predicition
of disease severity is feasible in NE. Most patients with
NE present with unspecific flu-like symptoms such as
headache and fever, but often develop severe flank pain
and oliguria soon afterwards. Laboratory analysis usually
demonstrates thrombocytopenia and elevated plasma
creatinine concentration at this stage. However, creatinine
is a tardy and unreliable marker of acute kidney injury.
Striking differences in peak creatinine concentration and
associated problems of AKI such as electrolyte distur-
bances and uremic symptoms are observed in patients.
Weight change during disease may indicate fluid retention
and could therefore be an additional marker of disease
severity reflecting capillary leakage [13, 14].
In this study, we show that uNGAL, and to a lesser de-
gree markers of proteinuria, are able to predict severity
of AKI. Severe AKI in turn can be associated with compli-
cations and the need for intensive monitoring of fluid- and
electrolyte status. In the case of uNGAL, its associations
with length of hospital stay and weight change during
hospital stay further underlines its role in predicting
disease severity. Thus, determination of uNGAL in patients
with suspected NE right upon first presentation could guide
the clinician’s decision about hospital admission. Our data
suggest that an uNGAL >130 ng/ml (positive predictive
value 90 %, cf. Table 5) is associated with severe AKI
prompting hospital admission for further monitoring.
In contrast, patients with low NGAL (<30 ng/ml) are at
a relatively low risk for severe AKI, and their care could
be continued in an outpatient setting. Adjustment for
urinary creatinine did not improve the correlation, as
also shown in a previous work [10].
Whereas thrombocytopenia also associated with length
of hospital stay in our study, it was not correlated with
other variables of disease severity. Since thrombocytopenia
Table 3 Correlation of laboratory markers with variables of disease severity; b. multivariate (adjusted for sex, age and BMI)
Peak plasma creatinine Duration of hospital stay Weight cycling Peak urine output
R2 βstd (p) R
2 βstd (p) R
2 βstd (p) R
2 βstd (p)
Leukocyte count 0.08 0.25 (0.068) 0.03 0.12 (0.383) 0.07 0.005 (0.97) 0.10 −0.12 (0.379)
Platelet count 0.03 −0.10 (0.456) 0.18 −0.41 (0.002) 0.12 −0.22 (0.09) 0.13 0.20 (0.129)
Plasma sodium 0.12 −0.32 (0.019) 0.13 −0.35 (0.010) 0.18 −0.35 (0.013) 0.09 −0.03 (0.839)
C-reactive protein 0.02 −0.05 (0.742) 0.10 0.29 (0.030) 0.09 −0.03 (0.85) 0.15 −0.26 (0.051)
Procalcitonin 0.38 0.62 (0.034) 0.41 0.80 (0.007) 0.12 0.42 (0.26) 0.05 −0.25 (0.446)
Urine protein/creatinine 0.44 0.70 (0.002) 0.13 0.32 (0.194) 0.11 0.31 (0.23) 0.08 0.04 (0.855)
Urine albumine/creatinine 0.40 0.67 (0.002) 0.19 0.43 (0.054) 0.20 0.40 (0.09) 0.09 0.08 (0.731)
Urinary NGAL 0.51 0.71 (<0.0001) 0.28 0.52 (<0.0001) 0.17 0.31 (0.0385) 0.08 0.01 (0.971)
Urinary NGAL/creatinine 0.47 0.68 (<0.0001) 0.17 0.41 (0.005) 0.17 0.31 (0.0385) 0.07 0.08 (0.605)
Table 4 Correlation of laboratory markers with variables of disease severity; c. multivariate models of peak plasma creatinine
concentration and duration of hospital stay (adjusted for sex, age, BMI, uACR, uNGAL)
Peak plasma creatinine Duration of hospital stay
R2 βstd (p) R2 βstd (p)
Sex 0.64 −0.10 (0.514) 0.53 −0.34 (0.07)
Age −0.06 (0.682) 0.39 (0.03)
BMI 0.04 (0.802) −0.30 (0.10)
Urine albumine/creatinine 0.37 (0.049) 0.27 (0.18)
Urinary NGAL 0.56 (0.004) 0.49 (0.02)
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is typical in early phases of NE, this association is probably
confounded by the time of presentation in the ER relative
to disease phase. Patients who tended to present at an
earlier disease phase would have lower platelet counts
and would therefore have to be observed longer until
resolution of AKI. Thrombocytopenia, however, could
prove to be a better predictor of disease severity if de-
termined early in the disease course, as shown by
Rasche et al. [15].
The underlying pathomechanisms of AKI in PUUV
infection is not fully understood. Although the virus
primarily replicates in endothelial cells, it does not
cause major cytotoxicity or cell death [2]. Rather, it
seems to transiently disrupt the integrity of cell-to-cell
junctions in renal podocytes, tubular epithelial and
glomerular endothelial cells [16]. However, the con-
trast of clear interstitial edema and occasional tubular
damage with relatively spared glomeruli seen in renal
biopsy specimens suggests that the majority of renal
pathology is due to tubulointerstitial injury [17–19].
NGAL predominantly accumulates in epithelial cells
of proximal tubules where it is thought to play a role
in induction of reepithelialization [20, 21]. Therefore,
the observed strong association of uNGAL with peak
plasma creatinine concentration, which was independent
of proteinuria, supports the predominantly tubulointersti-
tial injury in NE in two ways. NGAL produced by neutro-
phil cells is freely filtrated and reabsorbed at proximal
tubular sites [22]. Hence, proximal tubular injury would
result in increased NGAL excretion by reduced tubular
reabsorption. Furthermore, NGAL mRNA expression
and production is upregulated in the distal convoluted
tubule and the collecting duct during tubular stress
[23]. These mutually enhancing effects and the marked
tubulointerstitial injury in NE [17] could explain the
strong association of uNGAL with the severity of AKI.
Several other biomarkers have previously been associ-
ated with the severity of NE. These comprise plasma
markers such as interleukin-6 [24], indoleamin 2,3-diox-
ygenase [25], pentraxin-3 [13], cell-free DNA [26] and
the urinary biomarker GATA-3 [27]. One study found
that the maximum leukocyte count, which has been seen
3–6 days after disease onset, correlated with fold-change
in plasma creatinine [27]. As to our knowledge, association
of NGAL and simple urine biomarkers such as uACR or
uPCR with outcome variables has not been investigated be-
fore. uNGAL determined in the ER upon first presentation
of the patient seems to be the clinically most relevant and
robust predictor, which seems to be independent from
disease phase and time of onset of symptoms.
The single most important limitation of our study is
its retrospective aspect. In a university hospital setting,
we also note that the patients in our cohort were admit-
ted at a relatively late disease phase (median 6 days after
the onset of first symptoms), which potentially explains
why established early markers of disease severity such as
thrombocytopenia did not perform well.
Nevertheless, our robust findings support the notion
that uNGAL allows for prediction of severity of AKI, en-
abling a risk stratification of these patients upon first
presentation in the ER for suspected NE. Future trials
have to prospectively validate these results.
Conclusion
Urinary NGAL, determined upon hospital admission accur-
ately predicts severity of acute kidney injury in Puumala
virus infection and allows for early risk stratification in
these patients. Further trials are required to validate these
findings prospectively.
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Table 5 Odds ratio (OR) for developing AKIN stage 3 acute kidney injury
OR Lower CI Upper CI p AUC-ROC
Urinary protein/creatinine ratio 4.71 1.04 46 0.04 0.71
Urinary albumin/creatinine ratio 4.11 1.33 21.68 0.01 0.75
uNGAL 5.97 2.35 21.65 0.001 0.80
Odds ratio (OR) for developing AKIN stage 3 acute kidney injury per 10-fold increase in urine protein/creatinine ratio, urine albumin/creatinine ratio and
urinary NGAL
Table 6 NGAL cutoff
uNGAL (ng/ml) <30a 30 – 130 >130b
uACR (mg/g) <200a 200–2000 >2000b
Risk of severe acute kidney injury low intermediate high
An example for urinary neutrophil gelatinase associated lipocalin (uNGAL) and
uACR (urine albumin creatinine ratio) cutoffs to facilitate clinical decision-making
in NE. Severe AKI is classified as an increase of plasma creatinine to >= 3x of
baseline (AKIN stage 3)
acutoff with high sensitivity (>90 %)
bcutoff with high specificity (>90 %)
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